Abilify (aripiprazole) is an atypical antipsychotic drug, approved by the FDA in 2002 to treat bipolar disorder, major depression, and schizophrenia. It is often used in tandem with other medications to treat major depression. Abilify was developed by Otsuka Pharmaceutical and marketed in collaboration with Bristol Myers Squibb. It was the top-selling pharmaceutical drug in the U.S. in 2013 and 2014. A generic version was approved on April 28, 2015.
Case Quick Facts
Abilify is chemically classified as a partial and full dopamine agonist. Agonists activate receptors in the brain, whereas antagonists block receptors.
Dopamine is a neurotransmitter that plays a large role in the brain’s reaction to reward and pleasure. Aripiprazole works by partially blocking dopamine at the D2 receptor and by more strongly stimulating the D3 dopamine receptor. This effect of partially blocking D2 and stimulating D3 results in the D3 receptor being overstimulated. The over-stimulation of the D3 receptor can cause compulsive behaviors, including gambling, eating, shopping, and sexual behavior.
Abilify can cause compulsive behavior in many forms, including gambling, eating, sexual behavior, and shopping. GoldenbergLaw is investigating cases where an individual’s primary loss is sustained through compulsive gambling. Losses from gambling are both quantifiable and catastrophic/life-altering and can result in:
- Drained bank accounts and 401ks
- Damaged personal and professional relationships
- Home foreclosures
- Criminal charges
The defendants in Abilify cases are Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Co., Ltd., and Bristol Myers Squibb Co.
On October 3, 2016, the United States Judicial Panel on Multidistrict Litigation consolidated pretrial proceedings for Abilify cases pending across the country. The resultant Abilify multidistrict litigation (MDL) is currently before Judge M. Casey Rodgers in the Northern District of Florida. GoldenbergLaw’s Marlene Goldenberg has been appointed to the Plaintiffs’ Steering Committee for the MDL and serves as the litigation’s Discovery Liaison.
Because GoldenbergLaw’s Marlene Goldenberg is so closely connected to Abilify litigation matters, our firm is the ideal choice for those looking to recover damages. Get in touch with our team to learn more about how we can help you navigate litigation.Do I Qualify?
If you or a loved one suffered from pathological gambling while taking Abilify, please call an Abilify lawyer on our team today and get a free consultation. If you’re considering filing for an Abilify gambling addiction lawsuit, our team can walk you through your legal options.Contact Us Call 800-903-1643
Studies and Reports
Scientific literature has identified dopamine as a potential cause of pathological gambling for years.
Chau et al., The Neural Circuitry of Reward and Its Relevance to Psychiatric Disorders
Studies and Reports
The European Medicines Agency declined to approve Abilify as an add-on treatment for depression because of concerns about its efficacy for that indication.
European Medicines Agency, Withdrawal Assessment Report for Abilify (Jan. 20, 2010)
Studies and Reports
According to a rigorous study by the Cochrane Collaboration, there is limited evidence that Abilify leads to symptom reduction when added to antidepressants, and side effects are more frequent under Abilify augmentation treatment.
K. Komossa et al., Second-Generation Antipsychotics for Major Depressive Disorder and Dysthymia (Review)
Why Choose GoldenbergLaw?
If you think that your next move should be a gambling addiction lawsuit, our team should be the first you call. We have years of experience working with not only Abilify cases but all sorts of drug and medical cases. Rest assured that should you partner with us, your case will be handled by a knowledgeable and dedicated staff.
Over 30 Years of Experience
Collaborative Approach to Litigation
Open and Honest Representation
Meet Your Abilify Team
Have a potential client we could help?
Call us. You’ll sleep better.